Qualitative Concept – Page 7

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

1 month ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

1 month ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, J&J, Lynozyfic, Multiple Myeloma, Neoplasms, Pfizer, Regeneron

Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology

Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

1 month ago talkbio0Tagged BCG Vaccine, Event-Free Survival, Inhibitor, Invasive, Malignant neoplasm of urinary bladder, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Overall Survival, PDCD1 gene, Phase 3 CREST trial, Sasanlimab, subcutaneous administration

Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration

Keytruda around head and neck cancer surgery cuts chance of disease coming back

1 month ago talkbio0Tagged Episodic, Head, Keytruda, perioperative

Keytruda, Head, perioperative, Episodic

J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing

1 month ago talkbio0Tagged Malignant neoplasm of urinary bladder, TAR 200, United States Food and Drug Administration, Urinary Bladder

Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder

Akeso’s PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer

1 month ago talkbio0Tagged Akeso, Akeso 's, Anniko, Approved, Inhibitor, Nasopharyngeal carcinoma, PDCD1 gene, United States Food and Drug Administration

United States Food and Drug Administration, Approved, Akeso, Nasopharyngeal carcinoma, PDCD1 gene, Inhibitor, Akeso ‘s, Anniko

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

1 month ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%